Literature DB >> 9740247

Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions.

R C Geertsen1, G F Hofbauer, F Y Yue, S Manolio, G Burg, R Dummer.   

Abstract

Expression of HLA class I molecules is essential for the recognition of tumor cells by CD8+ T cells. In this study, 48 bioptic samples of 42 patients in all stages of melanoma were investigated after short-time cultivation of tumor cells. To confirm melanocytic origin of cultured cells, samples were screened for mRNA expression of melanoma markers gp100, tyrosinase, MAGE-3, MelanA, and MUC18 by reverse transcriptase-polymerase chain reaction. Surface expression of specific HLA-A and -B allospecificities on melanoma cells were analyzed with a standard microcytotoxicity assay after stimulation with interferon (IFN)-alpha and compared with the background found in peripheral blood mononuclear cells from the corresponding patients. Immunohistochemistry and flow cytometry confirmed specific losses in cases where the appropriate monoclonal antibodies were available. The level of expression of HLA-I, HLA-II, and intercellular adhesion molecule 1 antigens on melanoma cells cultured in the presence or absence of IFN-alpha and IFN-gamma was determined cytofluorometrically. All cell cultures tested were found to be positive for one or more melanocytic markers by reverse transcriptase-polymerase chain reaction. The specific HLA-I alleles on the cultured cells were detectable in 45 of 48 samples. In 11 cases a specific loss of one HLA-I allele was observed (2 x A2, B7, B8, B18, 4XB44, B47, B49). Ten of these samples were derived from locoregional lymphnode metastases or from distant metastatic tumors. Only one sample from a primary melanoma showed a specific loss of HLA-I (B47). IFN-alpha upregulated expression of HLA-I up to 4-fold. IFN-gamma enhanced the appearance of HLA-II up to 35-fold and the expression of intercellular adhesion molecule 1 up to 40-fold. Selective loss of HLA-I allospecificities might be a major step in tumor progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740247     DOI: 10.1046/j.1523-1747.1998.00305.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

1.  Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro.

Authors:  Alessandra Curioni Fontecedro; Verena Lutschg; Ossia Eichhoff; Reinhard Dummer; Urs F Greber; Silvio Hemmi
Journal:  Virol J       Date:  2010-07-29       Impact factor: 4.099

2.  Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response.

Authors:  Randall S MacGill; Thomas A Davis; Jennifer Macko; Helena J Mauceri; Ralph R Weichselbaum; C Richter King
Journal:  Clin Exp Metastasis       Date:  2007-07-25       Impact factor: 5.150

3.  Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma.

Authors:  Phil F Cheng; Olga Shakhova; Daniel S Widmer; Ossia M Eichhoff; Daniel Zingg; Sandra C Frommel; Benedetta Belloni; Marieke Ig Raaijmakers; Simone M Goldinger; Raffaella Santoro; Silvio Hemmi; Lukas Sommer; Reinhard Dummer; Mitchell P Levesque
Journal:  Genome Biol       Date:  2015-02-22       Impact factor: 13.583

4.  The RGD-binding integrins αvβ6 and αvβ8 are receptors for mouse adenovirus-1 and -3 infection.

Authors:  Manuela Bieri; Rodinde Hendrickx; Michael Bauer; Bin Yu; Tania Jetzer; Birgit Dreier; Peer R E Mittl; Jens Sobek; Andreas Plückthun; Urs F Greber; Silvio Hemmi
Journal:  PLoS Pathog       Date:  2021-12-15       Impact factor: 6.823

5.  HLA-B8 association with late-stage melanoma--an immunological lesson?

Authors:  Joachim Fensterle; Uwe Trefzer; Thomas Berger; Mads Hald Andersen; Selma Ugurel; Jürgen C Becker
Journal:  BMC Med       Date:  2006-03-13       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.